Andere Sprachen Alzinova AB

Aktien

A2N87T

SE0007413455

ALZ

Markt geschlossen - Nasdaq Stockholm Andere Börsenplätze 17:29:53 03.05.2024			% 5 Tage	% 1. Jan.
1,262 ^SEK	+12,28 %		+9,17 %	-58,42 %

25.04.	Schwedisches Unternehmen Alzinova gibt bekannt, dass CEO bis Ende Juli zurücktritt	MT
25.04.	Kristina Torfgård verlässt den CEO-Posten bei Alzinova Ab mit Wirkung zum 31. Juli 2024	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

NOTICE OF ANNUAL GENERAL MEETING IN ALZINOVA AB (PUBL)	26.04.
The Board of Directors resolves on a rights issue of shares of approximately SEK 34.4 million	26.04.
Sweden’s Alzinova Says CEO to Step Down by July-end	25.04.
Kristina Torfgård leaves the CEO position at Alzinova AB in July 2024	25.04.
Kristina Torfgård Leaves the CEO Position At Alzinova Ab, Effective July 31, 2024	25.04.
Alzinova: In-depth analysis shows positive trend in biomarkers	11.04.
Alzinova AB Completes In-Depth Analysis of Data from Part A of Alzinova's Phase 1B Study with the Vaccine Candidate ALZ-101	11.04.
Alzinova - All patients in the extension part of the phase 1b study have received their last dose	04.04.
Alzinova AB Announces All Patients in the Extension Part of the Phase 1B Study Have Received Their Last Dose of ALZ-101	04.04.
Sweden's Alzinova Names Interim CFO	08.03.
Alzinova appoints Erik Kullgren as interim CFO	08.03.
Alzinova AB Announces CFO Changes	08.03.
Alzinova presents at investor meetings in March	05.03.
Alzinova Q4 – With wind in the sails	28.02.
Alzinova publishes Year-end report 2023	28.02.
Alzinova AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	28.02.
Alzinova Secures Regulatory Approval to Test Higher Dose of Vaccine Candidate in Ongoing Trial	13.02.
Alzinova receives regulatory approval to evaluate a higher dose	13.02.
Alzinova AB Receives Regulatory Approval to Evaluate A Higher Dose of the Vaccine Candidate Alz-101 in the Ongoing Phase 1B Study	13.02.
SynAct Pharma Names New Chief Medical Officer	01.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Alzinova AB

Aktien

A2N87T

SE0007413455

ALZ

Andere Sprachen

Filter